Elanco Animal Health Incorporated (ELAN) |
|
10.96 -0.28 (-2.49%)
|
10-02 16:00 |
|
Open: |
11.22 |
Pre. Close: |
11.24 |
|
High:
|
11.22 |
Low:
|
10.879 |
|
Volume:
|
3,486,601 |
Market Cap:
|
5,400(M) |
|
|
|
Technical analysis |
as of: 2023-10-02 4:49:46 PM |
|
Short-term rate:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 13.99 One year: 14.79 |
| Support: |
Support1: 10.87 Support2: 9.05 |
| Resistance: |
Resistance1: 11.98 Resistance2: 12.67 |
| Pivot: |
11.49 |
| Moving Average: |
MA(5): 11.17 MA(20): 11.57
MA(100): 10.74  MA(250): 11.28 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 14.6 %D(3): 15.7 |
| RSI: |
RSI(14): 36.8 |
| 52-week: |
High: 14.68 Low: 7.88 |
| Average Vol(K): |
3-Month: 5,485 (K) 10-Days: 3,330 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ELAN ] has closed above bottom band by 8.6%. Bollinger Bands are 13.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.23 - 11.29 |
11.29 - 11.34 |
|
Low:
|
10.74 - 10.81 |
10.81 - 10.86 |
|
Close:
|
10.85 - 10.96 |
10.96 - 11.06 |
|
Company Description |
|
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana. |
Headline News |
Mon, 02 Oct 2023
SG Americas Securities LLC Purchases Shares of 24369 Elanco ... - MarketBeat
Sat, 23 Sep 2023
First-of-its-kind parvo treatment may revolutionize care for highly ... - USA TODAY
Fri, 22 Sep 2023
Sciencast Management LP Acquires Stake in Elanco Animal Health ... - Best Stocks
Tue, 19 Sep 2023
New Strong Buy Stocks for September 19th - Nasdaq
Fri, 15 Sep 2023
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Bought by ... - MarketBeat
Sun, 10 Sep 2023
Franklin Resources Inc. Significantly Reduces Stake in Elanco ... - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
493 (M) |
| Shares Float |
491 (M) |
|
% Held by Insiders
|
0.5 (%) |
|
% Held by Institutions
|
100.7 (%) |
|
Shares Short
|
10,360 (K) |
|
Shares Short P.Month
|
10,140 (K) |
Stock Financials |
|
EPS
|
-0.22 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
15.06 |
|
Profit Margin (%)
|
-2.7 |
|
Operating Margin (%)
|
8.2 |
|
Return on Assets (ttm)
|
1.4 |
|
Return on Equity (ttm)
|
-1.6 |
|
Qtrly Rev. Growth
|
-10 |
|
Gross Profit (p.s.)
|
5.07 |
|
Sales Per Share
|
8.76 |
|
EBITDA (p.s.)
|
1.97 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
118 (M) |
|
Levered Free Cash Flow
|
88 (M) |
Stock Valuations |
|
PE Ratio
|
-49.82 |
|
PEG Ratio
|
-66.7 |
|
Price to Book value
|
0.72 |
|
Price to Sales
|
1.24 |
|
Price to Cash Flow
|
45.76 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
